Editing Infliximab

{{Short description|Biopharmaceutical drug for autoimmune disorders}}
{{Use dmy dates|date=May 2024}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{infobox drug
| Verifiedfields    = changed
| verifiedrevid     = 458271995
| type = mab
| image             = Infliximab_structure2.jpg
| width             = 
| alt               = 
| caption           =

<!-- Monoclonal antibody data -->
| mab_type = mab
| source = xi/o
| target = [[Tumor necrosis factors]] (TNF)

<!-- Clinical data -->
| pronounce         = 
| tradename         = Remicade
| Drugs.com         = {{drugs.com|monograph|infliximab}}
| MedlinePlus       = a604023
| DailyMedID        = Infliximab
| pregnancy_AU      = C
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Infliximab Use During Pregnancy | website=Drugs.com | date=2 July 2019 | url=https://www.drugs.com/pregnancy/infliximab.html | access-date=13 August 2020 | archive-date=30 November 2020 | archive-url=https://web.archive.org/web/20201130151454/https://www.drugs.com/pregnancy/infliximab.html | url-status=live }}</ref>
| pregnancy_category= 
| routes_of_administration = [[Intravenous]], [[Subcutaneous administration|subcutaneous]]
| class             = 
| ATC_prefix        = L04
| ATC_suffix        = AB02
| ATC_supplemental  = 
| biosimilars = infliximab-abda,<ref name="Renflexis FDA approval" /> infliximab-axxq,<ref name="Avsola FDA approval" /> infliximab-dyyb,<ref name="Inflectra FDA approval" /> infliximab-qbtx,<ref name="Ixifi FDA approval" /> Avsola,<ref name="Avsola FDA approval" /> Flixabi,<ref name="Flixabi EPAR" /> Inflectra,<ref name="Inflectra FDA approval" /><ref name="CA 2016 Highlights" /> Ixifi,<ref name="Ixifi FDA approval" /> Remsima,<ref name="CA 2016 Highlights" /> Renflexis,<ref name="Renflexis FDA approval" /><ref>{{cite web | title=Arthritis | website=[[Health Canada]] | date=8 May 2018 | url=https://www.canada.ca/en/services/health/drug-health-products/drug-medical-device-highlights-2017/approved-drugs/arthritis.html | access-date=13 April 2024}}</ref><ref>{{cite web | title=Regulatory Decision Summary for Renflexis | website=Drug and Health Products Portal | date=1 December 2017 | url=https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00305 | access-date=13 April 2024}}</ref> Zessly, Zymfentra<ref name="Zymfentra PR" />

<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment = 
| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment = 
| legal_CA = Rx-only
| legal_CA_comment = /&nbsp;Schedule D<ref>{{cite web | title=Health product highlights 2021: Annexes of products approved in 2021 | website=[[Health Canada]] | date=3 August 2022 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-product-highlights-2021/appendices.html | access-date=25 March 2024 | archive-date=25 March 2024 | archive-url=https://web.archive.org/web/20240325234307/https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-product-highlights-2021/appendices.html | url-status=live }}</ref><ref>{{cite web | title=Regulatory Decision Summary for Remsima SC | website=Drug and Health Products Portal | date=15 February 2024 | url=https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1708630999500 | access-date=2 April 2024 | archive-date=2 April 2024 | archive-url=https://web.archive.org/web/20240402033003/https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1708630999500 | url-status=live }}</ref><ref name="CA 2016 Highlights">{{cite web | title=Health Canada New Drug Authorizations: 2016 Highlights | website=[[Health Canada]] | date=14 March 2017 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2016-highlights.html | access-date=7 April 2024 | archive-date=7 April 2024 | archive-url=https://web.archive.org/web/20240407045431/https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2016-highlights.html | url-status=live }}</ref>
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = POM
| legal_UK_comment = 
| legal_US = Rx-only
| legal_US_comment = <ref name="Remicade FDA label">{{cite web | title=Remicade- infliximab injection, powder, lyophilized, for solution | website=DailyMed | date=8 April 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257 | access-date=22 May 2024}}</ref><ref>{{cite web | title=Avsola- infliximab-axxq injection, powder, lyophilized, for solution | website=DailyMed | date=7 April 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de34bcb7-b524-45c8-9181-61c6f48d540e | access-date=22 May 2024}}</ref><ref>{{cite web | title=Inflectra- infliximab-dyyb injection, powder, lyophilized, for solution | website=DailyMed | date=5 April 2024 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f | access-date=22 May 2024}}</ref><ref>{{cite web | title=Renflexis- infliximab injection, powder, lyophilized, for solution | website=DailyMed | date=26 January 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3827e1be-f328-45f7-b113-311b57039f8c | access-date=22 May 2024}}</ref><ref>{{cite web | title=Zymfentra- infliximab-dyyb injection | website=DailyMed | date=2 May 2024 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a193ab-9f96-4da6-aa7c-31212e81879a | access-date=22 May 2024}}</ref>
| legal_EU          = Rx-only
| legal_EU_comment  = <ref name="Remicade EPAR" /><ref name="Flixabi EPAR" /><ref name="Remsima EPAR" /><ref name="Inflectra EPAR" /><ref name="Zessly EPAR" />
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment = 
| legal_status      = <!--For countries not listed above-->

<!-- Pharmacokinetic data -->
| bioavailability   = 92% (IV, if 8% left in the syringe)
| protein_bound     = 
| metabolism        = [[reticuloendothelial]] system
| metabolites       = 
| onset             = 
| elimination_half-life = 9.5 days
| duration_of_action = 
| excretion         =

<!-- Identifiers -->
| CAS_number_Ref    = {{cascite|correct|??}}
| CAS_number        = 170277-31-3
| CAS_supplemental  = 
| PubChem           = 
| IUPHAR_ligand     = 
| DrugBank_Ref      = {{drugbankcite|correct|drugbank}}
| DrugBank          = DB00065
| ChemSpiderID_Ref  = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = none
| UNII_Ref          = {{fdacite|correct|FDA}}
| UNII              = B72HH48FLU
| KEGG_Ref          = {{keggcite|correct|kegg}}
| KEGG              = D02598
| ChEBI_Ref         = 
| ChEBI             = 
| ChEMBL_Ref        = {{ebicite|changed|EBI}}
| ChEMBL            = 1201581
| NIAID_ChemDB      = 
| PDB_ligand        = 
| synonyms          =

<!-- Chemical and physical data -->
| IUPAC_name        = 
| C=6428 | H=9912 | N=1694 | O=1987 | S=46
| SMILES            = 
| StdInChI          = 
| StdInChI_comment  = 
| StdInChIKey       = 
| density           = 
| density_notes     = 
| melting_point     = 
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| sol_units         = 
| specific_rotation = 
}}

<!-- Definition and medical uses -->
'''Infliximab''', a chimeric monoclonal antibody, sold under the brand name '''Remicade''' among others, is a medication used to treat a number of [[autoimmune diseases]]. This includes [[Crohn's disease]], [[ulcerative colitis]], [[rheumatoid arthritis]], [[ankylosing spondylitis]], [[psoriasis]], [[psoriatic arthritis]], and [[Behçet's disease]].<ref name=AHFS2019/> It is given by [[intravenous therapy|slow injection into a vein]], typically at six- to eight-week intervals.<ref name=AHFS2019/>

<!-- Side effects and mechanism -->
Common side effects include infections, [[acute infusion reaction]]s, and abdominal pain.<ref name=AHFS2019/> Infliximab is a [[chimeric protein|chimeric]] [[monoclonal antibody]] [[Biopharmaceutical|biologic]]. It seems to work by binding to and neutralizing [[TNF alpha|TNF-α]], preventing it from interacting with its [[receptor (biochemistry)|receptors]] on the cell.<ref name=AHFS2019/> TNF-α is a chemical messenger ([[cytokine]]) and a key part of the autoimmune reaction.

<!-- History and culture -->
Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are [[monoclonal antibody|monoclonal antibodies]] and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a "chimeric monoclonal antibody".<ref>{{cite journal | vauthors = Mouser JF, Hyams JS | title = Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease | journal = Clinical Therapeutics | volume = 21 | issue = 6 | pages = 932–42; discussion 931 | date = June 1999 | pmid = 10440618 | doi = 10.1016/s0149-2918(99)80015-0 }}</ref>{{medical citation needed|date=August 2020}}

Infliximab was approved for medical use in the United States in 1998,<ref name=AHFS2019>{{cite web |title=Infliximab, Infliximab-dyyb Monograph for Professionals |url=https://www.drugs.com/monograph/infliximab-infliximab-dyyb.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=15 July 2019 |archive-date=15 July 2019 |archive-url=https://web.archive.org/web/20190715045122/https://www.drugs.com/monograph/infliximab-infliximab-dyyb.html |url-status=live }}</ref> and in the European Union in August 1999.<ref name="Remicade EPAR">{{cite web | title=Remicade EPAR | website=[[European Medicines Agency]] (EMA) | date=10 August 2009 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/remicade | access-date=2 April 2020 | archive-date=22 October 2020 | archive-url=https://web.archive.org/web/20201022094956/https://www.ema.europa.eu/en/medicines/human/EPAR/remicade | url-status=live }}</ref> Infliximab [[biosimilar]]s have been approved in the EU (2013), in Japan (2014), and in the United States (2016, 2017, 2019).<ref name="Renflexis FDA approval" /><ref name="Ixifi FDA approval" /><ref name="Avsola FDA approval" /> It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO22nd">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 22nd list (2021) | year = 2021 | hdl = 10665/345533 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2021.02 | hdl-access=free }}</ref>
{{TOC limit}}

==Medical uses==

===Crohn's disease===
Three [[phenotype]]s, or categories of disease, are present in [[Crohn's disease]]: stricturing disease (which causes narrowing of the bowel), penetrating disease (which causes [[fistula]]e or abnormal connections of the bowel), and inflammatory disease (which primarily causes [[inflammation]]).<!--
--><ref name=phenotypes>{{cite journal | vauthors = Dubinsky MC, Fleshner PP | title = Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes | journal = Curr Treat Options Gastroenterol | volume = 6 | issue = 3 | pages = 183–200 | date = June 2003 | pmid = 12744819 | doi = 10.1007/s11938-003-0001-1 | s2cid = 21302609 }}</ref>

====Fistulizing disease====
Infliximab was first used for closure of fistulae in Crohn's disease in 1999. In a 94-patient, phase II clinical trial, the researchers showed infliximab was effective in closing fistulae between the [[skin]] and [[bowel]] in 56–68% of patients.<!--
--><ref name=Present>{{cite journal | vauthors = Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ | title = Infliximab for the treatment of fistulas in patients with Crohn's disease | journal = [[The New England Journal of Medicine]] | volume = 340 | issue = 18 | pages = 1398–405 | date = May 1999 | pmid = 10228190 | doi = 10.1056/NEJM199905063401804 | url = https://pure.uva.nl/ws/files/3156092/7456_77284y.pdf | access-date = 5 July 2019 | archive-date = 18 February 2019 | archive-url = https://web.archive.org/web/20190218233244/https://pure.uva.nl/ws/files/3156092/7456_77284y.pdf | url-status = live }}</ref> <!--
-->A large, 296-patient Phase III clinical trial called the ACCENT 2 trial showed infliximab was additionally beneficial in maintaining closure of fistulae, with almost two-thirds of all patients treated with the three initial doses of infliximab having a fistula response after 14 weeks, and 36% of patients maintaining closure of fistulae after a year, compared with 19% who received [[placebo]] therapy. This final trial resulted in the FDA approval of the drug to treat fistulizing disease.<!--
--><ref name=ACCENT2>{{cite journal | vauthors = Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ | title = Infliximab maintenance therapy for fistulizing Crohn's disease | journal = [[The New England Journal of Medicine]] | volume = 350 | issue = 9 | pages = 876–85 | date = February 2004 | pmid = 14985485 | doi = 10.1056/NEJMoa030815 | doi-access = free }}</ref>

====Inflammatory disease====
Infliximab has been used to induce and maintain remission in inflammatory Crohn's disease. The ACCENT 1 trial, a large, multicentre trial, found 39–45% of patients treated with infliximab, who had an initial response to it, maintained remission after 30 weeks, compared with 21% who received placebo treatment. It also showed a mean maintenance of remission from 38 to 54 weeks compared with 21 weeks for patients who received placebo treatment.<ref name=ACCENT1>{{cite journal | vauthors = Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P | title = Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | journal = Lancet | volume = 359 | issue = 9317 | pages = 1541–9 | date = May 2002 | pmid = 12047962 | doi = 10.1016/S0140-6736(02)08512-4 | s2cid = 1905194 }}</ref>

Crohn's patients have flares of their disease between periods of disease quiescence. Severe flares are usually treated with [[Prednisone|steroid]] medications to obtain remission, but steroids have many undesirable side effects, so some gastroenterologists are now advocating the use of infliximab as the first drug to try to get patients into [[remission (medicine)|remission]]. This has been called the top-down approach to treatment.<!--
--><ref name=topdown>{{cite journal | vauthors = Hanauer SB | title = Crohn's disease: step up or top down therapy | journal = Best Pract Res Clin Gastroenterol | volume = 17 | issue = 1 | pages = 131–7 | date = February 2003 | pmid = 12617888 | doi = 10.1053/bega.2003.0361 }}</ref>

===Ulcerative colitis===
Infliximab targets [[tumour necrosis factor|TNF]], thought to be more related to [[T helper cell#Th1/Th2 Model for helper T cells|Th1]] cytokines. Ulcerative colitis was thought to be a [[T helper cell#Th1/Th2 Model for helper T cells|Th2]] disease, and infliximab would be of limited use. However, patients with ulcerative colitis have begun to be treated with infliximab on the basis of two large clinical trials conducted in 2005 by Paul Rutgeerts and William Sandborn. The Acute ulcerative Colitis Treatment trials (ACT1 and ACT2) to evaluate the utility of infliximab in ulcerative colitis showed 44–45% of patients treated with infliximab for a year maintained a response to the medication, compared with 21% of patients who were treated with placebo medication. At two months, the response was 61–69% for patients treated with infliximab, and 31% for those treated with placebo.<ref name=ACT>{{cite journal | vauthors = Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF | title = Infliximab for induction and maintenance therapy for ulcerative colitis | journal = [[The New England Journal of Medicine]] | volume = 353 | issue = 23 | pages = 2462–76 | year = 2005 | pmid = 16339095 | doi = 10.1056/NEJMoa050516 | doi-access = free }}</ref>

===Psoriatic arthritis===
In [[psoriatic arthritis]] (PsA), inhibitors of TNF, such as infliximab, improve the signs and symptoms. Several therapies with modest efficacy have been studied in nail psoriasis. Among available agents, higher quality data are available to support the efficacy of [[cyclosporine]] and infliximab. Based on studies in AS, the results suggest infliximab, [[etanercept]], and [[adalimumab]] have the potential to reduce the signs and symptoms of moderate to severely active axial involvement in PsA in patients who have had an inadequate response to NSAID (level 1a, grade A). The anti-TNF agents (infliximab and etanercept; level 1b, grade A) are more effective for the treatment of [[enthesitis]] than traditional agents. Results suggest infliximab is effective for the treatment of [[dactylitis]] in PsA.<ref>{{cite journal | vauthors = Kavanaugh AF, Ritchlin CT | title = Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines | journal = J. Rheumatol. | volume = 33 | issue = 7 | pages = 1417–21 | date = July 2006 | pmid = 16724373 | collaboration = GRAPPA Treatment Guideline Committee }}</ref>

===Other===
It was approved for treating [[ankylosing spondylitis]],<ref name="Maxwell">{{cite journal | vauthors = Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA | title = TNF-alpha inhibitors for ankylosing spondylitis | journal = The Cochrane Database of Systematic Reviews | volume = 2015 | issue = 4 | pages = CD005468 | date = April 2015 | pmid = 25887212 | doi = 10.1002/14651858.CD005468.pub2 | pmc = 11200207 }}</ref> psoriatic arthritis, psoriasis, [[rheumatoid arthritis]].<ref>{{cite journal | vauthors = Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, Tugwell P | title = Infliximab for the treatment of rheumatoid arthritis | journal = The Cochrane Database of Systematic Reviews | volume = 2002 | issue = 3 | pages = CD003785 | date = 22 July 2002 | pmid = 12137712 | pmc = 8729322 | doi = 10.1002/14651858.cd003785 }}</ref>

Infliximab is also prescribed (out of indication) for the treatment of [[Behçet's disease]].<ref>{{cite journal | vauthors = Sfikakis PP | title = Behçet's disease: a new target for anti-tumour necrosis factor treatment | journal = Ann. Rheum. Dis. | volume = 61 | issue = Suppl 2 | pages = ii51–3 | date = November 2002 | pmid = 12379622 | pmc = 1766720 | doi = 10.1136/ard.61.suppl_2.ii51 }}</ref>

Infliximab is the most frequently used biological agent in treating [[relapsing polychondritis]].<ref name="Relapsing polychondritis">{{cite journal | vauthors = Puéchal X, Terrier B, Mouthon L, Costedoat-Chalumeau N, Guillevin L, Le Jeunne C | title = Relapsing polychondritis | journal = Joint Bone Spine | volume = 81 | issue = 2 | pages = 118–24 | date = March 2014 | pmid = 24556284 | doi = 10.1016/j.jbspin.2014.01.001 | s2cid = 205754989 | url = http://www.hal.inserm.fr/inserm-00951203 | access-date = 4 November 2018 | archive-date = 5 November 2018 | archive-url = https://web.archive.org/web/20181105015404/https://www.hal.inserm.fr/inserm-00951203 | url-status = live | url-access = subscription }}</ref> Half of the patients saw benefit from this treatment, and a few other patients experienced infections that in some cases lead to death.<ref name="Relapsing polychondritis"/><ref>{{cite journal | vauthors = Kemta Lekpa F, Kraus VB, Chevalier X | title = Biologics in relapsing polychondritis: a literature review | journal = Seminars in Arthritis and Rheumatism | volume = 41 | issue = 5 | pages = 712–9 | date = April 2012 | pmid = 22071463 | doi=10.1016/j.semarthrit.2011.08.006}}</ref>

There have been numerous case reports of the efficacy of infliximab in various inflammatory skin conditions diseases; the FDA approved infliximab for chronic severe [[plaque psoriasis]] in adults in September 2006.<ref>{{cite journal | vauthors = Gupta AK, Skinner AR | title = A review of the use of infliximab to manage cutaneous dermatoses | journal = J Cutan Med Surg | volume = 8 | issue = 2 | pages = 77–89 | year = 2004 | pmid = 15685387 | doi = 10.1007/s10227-004-0115-7 | s2cid = 23838714 }}</ref>

Infliximab has been used off-label in treating refractory [[sarcoidosis]], where other treatments have not been effective.<ref>{{cite journal | vauthors = Wijsenbeek MS, Culver DA | title = Treatment of Sarcoidosis | journal = Clinics in Chest Medicine | volume = 36 | issue = 4 | pages = 751–767 | date = December 2015 | pmid = 26593147 | doi = 10.1016/j.ccm.2015.08.015 }}</ref>

Infliximab has been tested in [[chronic obstructive pulmonary disease]] (COPD) but there was no evidence of benefit with the possibility of harm.<ref>{{cite journal | vauthors = Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J | title = The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease | journal = Am. J. Respir. Crit. Care Med. | volume = 175 | issue = 9 | pages = 926–34 | date = May 2007 | pmid = 17290043 | doi = 10.1164/rccm.200607-995OC }}</ref>

Infliximab is indicated for steroid refractory [[checkpoint inhibitor induced colitis]], at a dose of 5 to 10&nbsp;mg/kg.<ref name=Brahmer>{{cite journal | vauthors = Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA | title = Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline | journal = Journal of Clinical Oncology | volume = 36 | issue = 17 | pages = 1714–1768 | date = June 2018 | pmid = 29442540 | pmc = 6481621 | doi = 10.1200/JCO.2017.77.6385 }}</ref>

Infliximab has been found to be a safe alternative treatment to a second dose of [[Immunoglobulin therapy|IVIG]] for [[Kawasaki disease|Kawasaki Disease]] resistant to initial IVIG therapy, showing better outcomes in fever resolution and fewer severe adverse effects such as [[hemolytic anemia]].<ref>{{Cite web |date=2024-05-09 |title=Comparing Two Treatments for IVIG-Resistant Kawasaki Disease - Evidence Update for Clinicians |url=https://www.pcori.org/evidence-updates/comparing-two-treatments-ivig-resistant-kawasaki-disease |access-date=2024-06-30 |website=www.pcori.org |language=en}}</ref>

== Adverse effects ==
{{More citations needed section|date=November 2009}}

Infliximab has adverse effects, some life-threatening, common to drugs in the class of [[TNF inhibitor|TNF inhibiting]] [[immunosuppressants]] (which also includes etanercept ([[Enbrel]]) and adalimumab ([[Humira]])). Some of the most severe are:

* serious [[infection]]s
* reactivation of [[hepatitis B]]
* reactivation of [[tuberculosis]]<ref>{{cite journal | vauthors = Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM | title = Tuberculosis associated with infliximab, a tumor necrosis factor α–neutralizing agent | journal = N Engl J Med | volume = 345 | issue = 15 | pages = 1098–1104 | year = 2001 | pmid = 11596589 | doi = 10.1056/NEJMoa011110 | doi-access = free }}</ref>
* lethal [[hepatosplenic T-cell lymphoma]] (generally only when combined with [[6-mercaptopurine]])
* [[drug-induced lupus]]
* [[demyelinating]] [[central nervous system]] disorders
* [[psoriasis]] and psoriasiform skin lesions
* new-onset [[vitiligo]]

Cases of [[leukopenia]], [[neutropenia]], [[thrombocytopenia]], and [[pancytopenia]] (some fatal) have been reported with infliximab.<ref>{{cite web|url=http://www.remicade.com/remicade/global/hcp/healthcare_professionals.html|title=Remicade for Healthcare Professionals|website=Remicade|url-status=dead|archive-url=https://web.archive.org/web/20080704080738/http://www.remicade.com/remicade/global/hcp/healthcare_professionals.html|archive-date=4 July 2008}}</ref> The FDA issued a warning to doctors appearing in the respective product labeling of infliximab instructing them to screen and monitor potential patients more carefully.<ref>{{cite web | title = Remicade (infliximab) for IV Injection | date = May 2006 | publisher = U.S. [[Food and Drug Administration]] (FDA) | url = https://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf | archive-url = https://web.archive.org/web/20061009085444/https://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf| archive-date = 9 October 2006 }}</ref> The FDA issued a warning to doctors that there is an increased risk of lymphoma and other cancers associated with the use of infliximab and other tumor necrosis factor blockers in children and adolescents.<ref>{{cite web |url = https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalproducts/ucm175843.htm |title = Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) August 2009 |date = 31 August 2009 |publisher = U.S. [[Food and Drug Administration]] (FDA) |access-date = 15 November 2009 |url-status = dead |archive-url = https://web.archive.org/web/20091115213333/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm |archive-date = 15 November 2009 }} {{PD-notice}}</ref>

Maintenance therapy with the drug (versus intermittent or sporadic therapy) lessens the likelihood of developing antibodies to infliximab which are known to reduce the efficacy of the drug. Combination treatment with [[methotrexate]] (an antifolate drug which suppresses the immune system) has been shown to reduce the formation of these antibodies in patients with rheumatoid arthritis<ref>{{cite journal | vauthors = Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P | title = Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | journal = Lancet | volume = 354 | issue = 9194 | pages = 1932–9 | date = 4 December 1999 | pmid = 10622295 | doi = 10.1016/s0140-6736(99)05246-0 | s2cid = 104011 }}</ref> and combination therapy with other immunosuppressants has been shown to reduce the likelihood of these antibodies being formed in Crohn's disease.<ref name="ACCENT1"/> The use of immunosuppressants may not be necessary in all diseases for which infliximab is indicated, and indiscriminant uses of these other immunosuppressants carry their own risks. Infliximab was studied in monotherapy (without concomitant immunosuppressants such as methotrexate or [[azathioprine]]) in [[psoriasis]], [[psoriatic arthritis]], and [[ankylosing spondylitis]].<ref name="Maxwell" />

== Pharmacology ==
Infliximab is a purified, recombinant DNA-derived [[Chimeric antibody|chimeric]] human-mouse [[Immunoglobulin G|IgG]] [[monoclonal antibody]] that consists of mouse [[Antibody#Heavy chain|heavy]] and [[Antibody#Light chain types|light]] chain [[Antibody#Immunoglobulin domains|variable regions]] combined with human heavy and light chain constant regions.<ref name="Akiho1">{{cite journal | vauthors = Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H | title = Promising biological therapies for ulcerative colitis: A review of the literature | journal = World Journal of Gastrointestinal Pathophysiology | volume = 6 | issue = 4 | pages = 219–227 | date = November 2015 | pmid = 26600980 | pmc = 4644886 | doi = 10.4291/wjgp.v6.i4.219 | doi-access = free }}</ref> It has a [[Biological half-life|serum half-life]] of 9.5 days and can be detected in serum 8 weeks after infusion treatment.<ref name="Akiho1"/>

Infliximab neutralizes the biological activity of [[TNF alpha|TNF-α]] by binding with high [[Affinity (pharmacology)|affinity]] to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of [[T cells]] and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. Infliximab and [[adalimumab]] (another TNF antagonist) are in the subclass of "anti-TNF antibodies" (they are in the form of naturally occurring antibodies), and are capable of neutralizing all forms (extracellular-, [[transmembrane]]-, and [[Receptor (immunology)|receptor]]-bound) of TNF-α.<ref>{{cite journal | vauthors = Choy EH, Panayi GS | title = Cytokine pathways and joint inflammation in rheumatoid arthritis | journal = [[The New England Journal of Medicine]] | volume = 344 | issue = 12 | pages = 907–16 | date = March 2001 | pmid = 11259725 | doi = 10.1056/NEJM200103223441207 }}</ref> Etanercept, a third TNF antagonist, is in a different subclass (receptor-construct fusion protein), and, because of its modified form, cannot neutralize receptor-bound TNF-α.<ref>Etanercept product labeling</ref> Additionally, the anti-TNF antibodies [[adalimumab]] and infliximab have the capability of [[lysing]] cells involved in the inflammatory process, whereas the receptor fusion protein apparently lacks this capability.<ref>Etanercept, Adalimumab and Infliximab product labeling</ref>

Other monoclonal antibodies targeting TNF-α are [[golimumab]], [[adalimumab]], and [[certolizumab pegol]]. [[Etanercept]] also binds and inhibits the action of TNF-α, but is not a monoclonal antibody (it is instead a fusion of [[CD120|TNF-receptor]] and an [[Fc region|antibody constant region]]).<ref>{{cite journal | vauthors = Peppel K, Crawford D, Beutler B | title = A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity | journal = J. Exp. Med. | volume = 174 | issue = 6 | pages = 1483–9 | year = 1991 | pmid = 1660525 | pmc = 2119031 | doi = 10.1084/jem.174.6.1483 }}</ref>

==History==

The importance of TNF in the development of [[rheumatoid arthritis]] was originally demonstrated by [[George Kollias (biologist)|George Kollias]] and colleagues in proof of principle studies in transgenic animal models.<ref name="pmid1721867">{{cite journal |vauthors=Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G | title = Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis | journal = The EMBO Journal | volume = 10 | issue = 13 | pages = 4025–31 |date=December 1991 | pmid = 1721867 | pmc = 453150 | doi = 10.1002/j.1460-2075.1991.tb04978.x}}</ref><ref name="pmid26008591">{{cite journal |vauthors=Brenner D, Blaser H, Mak TW | title = Regulation of tumour necrosis factor signalling: live or let die. | journal = Nat Rev Immunol | volume = 15 | issue = 6 | pages = 362–74 | date=May 2015 | pmid = 26008591 | doi=10.1038/nri3834| s2cid = 1550839 | url = https://orbilu.uni.lu/bitstream/10993/58011/1/Brenner%20and%20Blaser%20et%20al_Nature%20Reviews%20Immunol%202015.pdf }}</ref>

Infliximab was developed by Junming Le (b. 1940) and [[Jan Vilček]] (b. 1933) at [[New York University School of Medicine]] and in collaboration with [[Centocor]] (now Janssen Biotech, Inc.).<ref>{{cite journal | vauthors = Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P | title = Construction and initial characterization of a mouse-human chimeric anti-TNF antibody | journal = Mol. Immunol. | volume = 30 | issue = 16 | pages = 1443–53 | date = November 1993 | pmid = 8232330 | doi = 10.1016/0161-5890(93)90106-L }}</ref>

==Society and culture==

===Marketing===

Remicade is marketed by [[Janssen Biotech]], Inc. (formerly [[Centocor]] Biotech, Inc.) in the United States, [[Mitsubishi Tanabe Pharma]] in Japan, [[Xian Janssen]] in China, and [[Schering-Plough]] (now part of [[Merck & Co]]) elsewhere.<ref name="JNJ_20071106_141812">{{cite press release |title = Remicade Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide |url = http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812 |publisher = [[Johnson & Johnson]] |date = 6 November 2007 |access-date = 14 November 2009 |url-status = dead |archive-url = https://web.archive.org/web/20110713111255/http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812 |archive-date = 13 July 2011 }}</ref>

===Biosimilars===
{{see also|Biosimilars}}

In June 2013, two [[biosimilar]] versions (Inflectra and Remsima) were submitted for approval in the European Union, by [[Hospira]] and Celltrion Healthcare respectively.<ref name=george2013>{{cite news |title=Billion-dollar biotech drug may soon have biosimilar competition | vauthors = George J |url=http://www.bizjournals.com/philadelphia/news/2013/06/28/biliion-dollar-biotech-drug-may-soon.html |work=[[Philadelphia Business Journal]] |date=28 June 2013 |access-date=27 June 2013 |url-status=live |archive-url=https://web.archive.org/web/20130701183938/http://www.bizjournals.com/philadelphia/news/2013/06/28/biliion-dollar-biotech-drug-may-soon.html |archive-date=1 July 2013 }}</ref> Both had a positive opinion from [[European Medicines Agency]]'s (EMA) Committee for Medicinal Products for Human Use (CHMP) for sale in the European Union (EU).<ref>{{cite web | url = http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001837.jsp&mid=WC0b01ac058004d5c1 | title = European Medicines Agency recommends approval of first two monoclonal-antibody biosimilars | archive-url = https://web.archive.org/web/20150217051925/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2013%2F06%2Fnews_detail_001837.jsp&mid=WC0b01ac058004d5c1 | archive-date=17 February 2015 | work = [[European Medicines Agency]] | date = 28 June 2013 }}</ref> Celltrion obtained marketing authorization approval (MAA) from 27 EU countries and 3 EEA (European Economic Area) countries by September 2013.<ref>{{cite news | vauthors = Rockoff JD | title=European Commission Approves Biosimilar of J&J and Merck's Remicade | website=[[The Wall Street Journal]] | date=10 September 2013 | url=https://www.wsj.com/articles/european-commission-approves-biosimilar-of-jj-and-mercks-remicade-1378844400 | access-date=1 March 2020 | archive-url=https://web.archive.org/web/20170125062916/http://www.wsj.com/articles/SB10001424127887324094704579067360123704206 |archive-date=25 January 2017|url-access=subscription }}</ref><ref name="Remsima EPAR">{{cite web | title=Remsima EPAR | website=[[European Medicines Agency]] (EMA) | date=4 October 2013 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/remsima | access-date=1 March 2020 | archive-date=29 December 2019 | archive-url=https://web.archive.org/web/20191229225040/https://www.ema.europa.eu/en/medicines/human/EPAR/remsima | url-status=live }}</ref><ref name="Inflectra EPAR">{{cite web | title=Inflectra EPAR | website=[[European Medicines Agency]] (EMA) | date=4 October 2013 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra | access-date=1 March 2020 | archive-date=16 October 2019 | archive-url=https://web.archive.org/web/20191016115847/https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra | url-status=live }}</ref> Inflectra was approved for use in the European Union in September 2013,<ref name="Inflectra EPAR" /> and Remsima was approved for use in the European Union in October 2013.<ref name="Remsima EPAR" />

In Japan, Celltrion received marketing authorization for Remsima from Japan's Ministry of Health, Labour and Welfare (MHLW) in July 2014.{{citation needed|date=March 2020}}

In India, Epirus Biopharmaceuticals obtained approval to produce biosimilar infliximab under the brand name "Infimab" (trail name BOW015).<ref>{{cite web| vauthors = Serebrov M |title=Epirus racks up its first biosimilar approval in India|url=http://www.bioworld.com/content/epirus-racks-its-first-biosimilar-approval-india-0|website=BioWorld|access-date=26 October 2014|url-status=live|archive-url=https://web.archive.org/web/20141029213733/http://www.bioworld.com/content/epirus-racks-its-first-biosimilar-approval-india-0|archive-date=29 October 2014}}</ref>

The US [[Food and Drug Administration]] (FDA) approved Celltrion/Hospira/Pfizer's Inflectra (infliximab-dyyb) in April 2016.<ref name="FDA PR 20191206">{{cite press release | title=FDA approves Inflectra, a biosimilar to Remicade | website=U.S. [[Food and Drug Administration]] (FDA) | date=6 December 2019 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade | archive-url=https://web.archive.org/web/20191207001439/https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade | archive-date=7 December 2019 | url-status=dead | access-date=6 December 2019}} {{PD-notice}}</ref><ref name="Inflectra FDA approval">{{cite web | title=Inflectra (infliximab-dyyb) for Injection | website=U.S. [[Food and Drug Administration]] (FDA) | date=27 June 2016 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000TOC.cfm | access-date=8 April 2024 | archive-date=20 May 2022 | archive-url=https://web.archive.org/web/20220520044426/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000TOC.cfm | url-status=dead }}</ref>

The FDA approved Samsung Bioepis Co., Ltd.'s Renflexis (infliximab-abda) in April 2017.<ref name="Renflexis FDA approval">{{cite web | title=Drug Approval Package: Renflexis (infliximab-abda) | website=U.S. [[Food and Drug Administration]] (FDA) | date=10 December 2018 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761054Orig1s000TOC.cfm | access-date=8 April 2024 | archive-date=18 December 2019 | archive-url=https://web.archive.org/web/20191218044927/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761054Orig1s000TOC.cfm | url-status=dead }}</ref>

[[Biogen]] released another biosimilar, Flixabi, which was approved in Germany, the UK, and the Netherlands.<ref name=biib>{{cite web|url=http://www.nasdaq.com/article/key-takeaways-from-biogens-q3-call-tecfidera-pipeline-biosimilars-cm699225/|title=Key Takeaways from Biogen's Q3 Call: Tecfidera, Pipeline, Biosimilars|date=27 October 2016|website=nasdaq.com|url-status=live|archive-url=https://web.archive.org/web/20161028083846/http://www.nasdaq.com/article/key-takeaways-from-biogens-q3-call-tecfidera-pipeline-biosimilars-cm699225/|archive-date=28 October 2016}}</ref> Flixabi was approved for use in the European Union in May 2016.<ref name="Flixabi EPAR">{{cite web | title=Flixabi EPAR | website=[[European Medicines Agency]] (EMA) | date=9 June 2016 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi | access-date=2 April 2020 | archive-date=16 October 2019 | archive-url=https://web.archive.org/web/20191016120357/https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi | url-status=live }}</ref>

In December 2017, Ixifi (infliximab-qbtx) was approved in the United States.<ref name="Ixifi FDA approval">{{cite web | title=Drug Approval Package: Ixifi (infliximab-qbtx) | website=U.S. [[Food and Drug Administration]] (FDA) | date=29 November 2018 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761072Orig1s000TOC.cfm | access-date=8 April 2024 | archive-date=18 December 2019 | archive-url=https://web.archive.org/web/20191218044952/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761072Orig1s000TOC.cfm | url-status=dead }}</ref>

Zessly was approved for use in the European Union in May 2018.<ref name="Zessly EPAR">{{cite web | title=Zessly EPAR | website=[[European Medicines Agency]] (EMA) | date=30 May 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/zessly | access-date=2 April 2020 | archive-date=30 December 2019 | archive-url=https://web.archive.org/web/20191230161426/https://www.ema.europa.eu/en/medicines/human/EPAR/zessly | url-status=live }}</ref>

In December 2019, Avsola (infliximab-axxq) was approved in the United States.<ref name="Avsola FDA approval">{{cite web | title=Drug Approval Package: Avsola | website=U.S. [[Food and Drug Administration]] (FDA) | date=30 January 2020 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761086Orig1s000TOC.cfm | access-date=8 April 2024 | archive-date=1 November 2020 | archive-url=https://web.archive.org/web/20201101090550/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761086Orig1s000TOC.cfm | url-status=dead }}</ref>

Avsola was approved for medical use in Canada in March 2020.<ref>{{cite web | title=Summary Basis of Decision (SBD) for Avsola | website=[[Health Canada]] | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00478&lang=en | access-date=29 May 2022 | archive-date=30 May 2022 | archive-url=https://web.archive.org/web/20220530221839/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00478&lang=en | url-status=live }}</ref>

In December 2021, Ixifi was approved for medical use in Canada.<ref>{{cite web | title=Summary Basis of Decision (SBD) for Ixifi | website=[[Health Canada]] | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00583&lang=en | access-date=29 May 2022 | archive-date=29 May 2022 | archive-url=https://web.archive.org/web/20220529192448/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00583&lang=en | url-status=live }}</ref>

=== Availability/affordability ===
Infliximab is supplied as a sterile, white, lyophilized (freeze-dried) powder,<ref>{{cite web|url=http://www.rxlist.com/remicade-drug.htm|title=Remicade (Infliximab): Side Effects, Interactions, Warning, Dosage & Uses|website=rxlist.com|url-status=live|archive-url=https://web.archive.org/web/20091218222855/http://www.rxlist.com/remicade-drug.htm|archive-date=18 December 2009}}</ref> so must be reconstituted and administered by a health care professional, usually in a hospital or office setting.<ref name="JNJ_20071106_141812" /> For this reason, it is usually covered under major medical insurance rather than prescription drug coverage. The loading regimen for all approved indications occurs at weeks 0, 2, and 6 at the above dosages.<ref name="JNJ_20071106_141812" />

In the UK, infliximab is available from the NHS for [[Crohn's disease]] treatment provided three criteria are met.<ref>{{cite web|url=http://guidance.nice.org.uk/TA40/Guidance|title=The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease - Guidance and guidelines - NICE|website=guidance.nice.org.uk|date=26 April 2002 |url-status=live|archive-url=https://web.archive.org/web/20100430172000/http://guidance.nice.org.uk/TA40/Guidance|archive-date=30 April 2010}}</ref> Patients should have severe active Crohn's disease with a [[Crohn's Disease Activity Index|CDAI]] score of 300 or more, have not responded to immunomodulating drugs and corticosteroids, and for whom surgery is inappropriate. Since February 2015, it is also approved for the treatment of [[ulcerative colitis]] where other treatments have not worked.<ref>{{cite web|url=http://www.nice.org.uk/guidance/ta329|title=Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |website=[[National Institute for Health and Care Excellence]] (NICE) |date=25 February 2015 |url-status=live|archive-url=https://web.archive.org/web/20150306044422/http://www.nice.org.uk/guidance/ta329|archive-date=6 March 2015}}</ref>

In Australia, infliximab is available through the PBS for Crohn's disease treatment provided the patient has not responded to conventional treatment and has a severe case of the condition.<ref>{{cite web|url=http://www.medicareaustralia.gov.au/provider/pbs/drugs1/crohns.jsp#N10041|title=Section 100 arrangements; only for infliximab|website=medicareaustralia.gov.au|url-status=dead|archive-url=https://web.archive.org/web/20110903072031/http://www.medicareaustralia.gov.au/provider/pbs/drugs1/crohns.jsp#N10041|archive-date=3 September 2011|access-date=20 August 2011}}</ref>

Johnson & Johnson reported in its 2013 annual report, "Remicade (infliximab), accounted for approximately 9.4% of the Company's total revenues for fiscal 2013."<ref>JNJ annual report, downloaded 22 April 2014. {{cite web |url=https://www.sec.gov/Archives/edgar/data/200406/000020040614000033/a2013122910-k.htm |title=2013 1229 10-K |access-date=1 September 2017 |url-status=live |archive-url=https://web.archive.org/web/20160305020323/http://www.sec.gov/Archives/edgar/data/200406/000020040614000033/a2013122910-k.htm |archive-date=5 March 2016 }}</ref>

Zymfentra was approved for medical use in the United States in October 2023.<ref name="Zymfentra PR">{{cite web | title=Celltrion USA Announces U.S. FDA Approval of Zymfentra (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease | publisher=Celltrion | via=Business Wire | date=22 October 2023 | url=https://www.businesswire.com/news/home/20231022057773/en/Celltrion-USA-Announces-U.S.-FDA-Approval-of-ZYMFENTRA%C2%AE-infliximab-dyyb-the-First-and-Only-Subcutaneous-infliximab-for-the-Treatment-of-People-With-Inflammatory-Bowel-Disease/ | access-date=25 December 2023 | archive-date=25 December 2023 | archive-url=https://web.archive.org/web/20231225100038/https://www.businesswire.com/news/home/20231022057773/en/Celltrion-USA-Announces-U.S.-FDA-Approval-of-ZYMFENTRA%C2%AE-infliximab-dyyb-the-First-and-Only-Subcutaneous-infliximab-for-the-Treatment-of-People-With-Inflammatory-Bowel-Disease/ | url-status=live }}</ref>

== References ==
{{reflist}}

==External links==
* {{commonscatinline}}

{{Schering-Plough|state=autocollapse}}
{{Immunosuppressants}}
{{Monoclonals for immune system}}
{{Portal bar | Medicine}}
{{Authority control}}

[[Category:Engineered proteins]]
[[Category:Immunosuppressants]]
[[Category:Drugs developed by Johnson & Johnson]]
[[Category:Janssen Biotech]]
[[Category:Janssen Pharmaceutica]]
[[Category:Drugs developed by Merck & Co.]]
[[Category:Monoclonal antibodies]]
[[Category:Drugs developed by Schering-Plough]]
[[Category:TNF inhibitors]]
[[Category:World Health Organization essential medicines]]